JP6320376B2 - リンパ球活性化遺伝子−３（ｌａｇ−３）へ結合する抗体の最適化およびその使用 - Google Patents

リンパ球活性化遺伝子−３（ｌａｇ−３）へ結合する抗体の最適化およびその使用 Download PDF

Info

Publication number
JP6320376B2
JP6320376B2 JP2015520635A JP2015520635A JP6320376B2 JP 6320376 B2 JP6320376 B2 JP 6320376B2 JP 2015520635 A JP2015520635 A JP 2015520635A JP 2015520635 A JP2015520635 A JP 2015520635A JP 6320376 B2 JP6320376 B2 JP 6320376B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
lag
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015520635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527880A (ja
Inventor
ニルス・ロンバーグ
モハン・スリニバサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48795938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6320376(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2015527880A publication Critical patent/JP2015527880A/ja
Application granted granted Critical
Publication of JP6320376B2 publication Critical patent/JP6320376B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015520635A 2012-07-02 2013-07-02 リンパ球活性化遺伝子−３（ｌａｇ−３）へ結合する抗体の最適化およびその使用 Active JP6320376B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261667058P 2012-07-02 2012-07-02
US61/667,058 2012-07-02
PCT/US2013/048999 WO2014008218A1 (en) 2012-07-02 2013-07-02 Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018071571A Division JP6668405B2 (ja) 2012-07-02 2018-04-03 リンパ球活性化遺伝子−３（ｌａｇ−３）へ結合する抗体の最適化およびその使用

Publications (2)

Publication Number Publication Date
JP2015527880A JP2015527880A (ja) 2015-09-24
JP6320376B2 true JP6320376B2 (ja) 2018-05-09

Family

ID=48795938

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015520635A Active JP6320376B2 (ja) 2012-07-02 2013-07-02 リンパ球活性化遺伝子−３（ｌａｇ−３）へ結合する抗体の最適化およびその使用
JP2018071571A Active JP6668405B2 (ja) 2012-07-02 2018-04-03 リンパ球活性化遺伝子−３（ｌａｇ−３）へ結合する抗体の最適化およびその使用
JP2020030795A Active JP7009531B2 (ja) 2012-07-02 2020-02-26 リンパ球活性化遺伝子－３（ｌａｇ－３）へ結合する抗体の最適化およびその使用
JP2022003192A Pending JP2022064901A (ja) 2012-07-02 2022-01-12 リンパ球活性化遺伝子－３（ｌａｇ－３）へ結合する抗体の最適化およびその使用
JP2024005837A Pending JP2024041966A (ja) 2012-07-02 2024-01-18 リンパ球活性化遺伝子－３（ｌａｇ－３）へ結合する抗体の最適化およびその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018071571A Active JP6668405B2 (ja) 2012-07-02 2018-04-03 リンパ球活性化遺伝子−３（ｌａｇ−３）へ結合する抗体の最適化およびその使用
JP2020030795A Active JP7009531B2 (ja) 2012-07-02 2020-02-26 リンパ球活性化遺伝子－３（ｌａｇ－３）へ結合する抗体の最適化およびその使用
JP2022003192A Pending JP2022064901A (ja) 2012-07-02 2022-01-12 リンパ球活性化遺伝子－３（ｌａｇ－３）へ結合する抗体の最適化およびその使用
JP2024005837A Pending JP2024041966A (ja) 2012-07-02 2024-01-18 リンパ球活性化遺伝子－３（ｌａｇ－３）へ結合する抗体の最適化およびその使用

Country Status (39)

Country Link
US (7) US9505839B2 (enExample)
EP (4) EP3795592B1 (enExample)
JP (5) JP6320376B2 (enExample)
KR (6) KR102126596B1 (enExample)
CN (2) CN108101991B (enExample)
AR (3) AR091649A1 (enExample)
AU (5) AU2013286914B2 (enExample)
BR (1) BR112014032999B1 (enExample)
CA (2) CA2877746C (enExample)
CL (1) CL2014003637A1 (enExample)
CO (1) CO7170127A2 (enExample)
CY (3) CY1119563T1 (enExample)
DK (3) DK2867258T3 (enExample)
EA (2) EA035013B1 (enExample)
ES (3) ES2831406T3 (enExample)
FI (2) FI3795592T3 (enExample)
FR (1) FR22C1057I2 (enExample)
HR (3) HRP20171315T1 (enExample)
HU (4) HUE069061T2 (enExample)
IL (1) IL236517B (enExample)
LT (4) LT3275899T (enExample)
LU (1) LUC00286I2 (enExample)
MX (2) MX365417B (enExample)
MY (3) MY197544A (enExample)
NL (1) NL301205I2 (enExample)
NO (2) NO2023008I1 (enExample)
NZ (1) NZ628528A (enExample)
PE (4) PE20150221A1 (enExample)
PH (2) PH12021552200A1 (enExample)
PL (2) PL2867258T3 (enExample)
PT (3) PT3795592T (enExample)
RS (3) RS56398B1 (enExample)
SG (2) SG11201408780XA (enExample)
SI (3) SI3795592T1 (enExample)
SM (3) SMT202000628T1 (enExample)
TN (1) TN2014000536A1 (enExample)
TW (7) TWI662046B (enExample)
UY (1) UY34887A (enExample)
WO (1) WO2014008218A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020103301A (ja) * 2012-07-02 2020-07-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ リンパ球活性化遺伝子−３（ｌａｇ−３）へ結合する抗体の最適化およびその使用

Families Citing this family (563)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4361545B2 (ja) * 2005-05-09 2009-11-11 小野薬品工業株式会社 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
HRP20151102T1 (xx) * 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
HUE025726T2 (en) 2009-03-25 2016-04-28 Genentech Inc Anti-FGFR3 antibodies and their use
ES2834093T3 (es) 2011-07-21 2021-06-16 Sumitomo Dainippon Pharma Oncology Inc Inhibidores de proteína quinasa heterocíclicos
HRP20201113T1 (hr) * 2013-03-15 2020-10-30 Glaxosmithkline Intellectual Property Development Limited Vežući proteini protiv lag-3
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
MX2016000750A (es) * 2013-08-02 2016-08-05 Aduro Biotech Holdings Europe B V Combinacion de agonistas de cd27 e inhibicion del punto de control inmunologico para estimulacion del sistema inmunologico.
DK3508502T5 (da) * 2013-09-20 2024-09-02 Bristol Myers Squibb Co Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
EA201990240A1 (ru) 2013-12-24 2019-06-28 Бристол-Маерс Сквибб Компани Новые трициклические соединения в качестве противораковых средств
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
HUE057817T2 (hu) * 2014-01-28 2022-06-28 Bristol Myers Squibb Co Anti-LAG-3 antitestek haematológiai malignitások kezelésére
CA2938193C (en) 2014-01-31 2023-05-02 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
KR20240110004A (ko) * 2014-03-14 2024-07-12 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
SI3122745T1 (sl) 2014-03-24 2019-05-31 Novartis Ag Organske spojine monobaktama za zdravljenje bakterijskih infekcij
ES2901705T3 (es) 2014-06-06 2022-03-23 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
EP3151820A4 (en) 2014-06-06 2017-11-22 Flexus Biosciences, Inc. Immunoregulatory agents
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3177593A1 (en) 2014-08-06 2017-06-14 Novartis AG Quinolone derivatives as antibacterials
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
JP2017535528A (ja) 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
CA3220466A1 (en) 2014-10-29 2016-05-06 Bicyclerd Limited Bicyclic peptide ligands specific for mt1-mmp
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
WO2016073738A2 (en) 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents
SI3221363T1 (sl) 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Protitelesa proti CD73 in njihova uporaba
WO2016094639A1 (en) * 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
ES2756300T3 (es) 2014-12-16 2020-04-27 Novartis Ag Compuestos de ácido isoxazol hidroxámico como inhibidores de LpxC
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
CA2971732A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
US11116838B2 (en) 2015-01-29 2021-09-14 The Trustees Of The University Of Pennsylvania Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
JP6774421B2 (ja) * 2015-02-19 2020-10-21 フュージョン ファーマシューティカルズ インク． がんの治療のための方法、組成物、及びキット
KR20170122799A (ko) 2015-03-02 2017-11-06 리겔 파마슈티칼스, 인크. TGF-β 억제제
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
US10399933B2 (en) 2015-04-03 2019-09-03 Bristol-Myers Squibb Company Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
HUE053903T2 (hu) 2015-04-13 2021-07-28 Five Prime Therapeutics Inc Kombinációs terápia rák ellen
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
WO2016183114A1 (en) 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016183115A1 (en) 2015-05-12 2016-11-17 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
ES2921350T3 (es) 2015-05-18 2022-08-24 Sumitomo Pharma Oncology Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
SG10202008304TA (en) 2015-05-29 2020-10-29 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
BR112017026025A2 (pt) 2015-06-03 2018-08-14 Boston Biomedical Inc composições que compreendem um inibidor de stemness de câncer e um agente imunoterápico para uso no tratamento de câncer
EA039293B1 (ru) * 2015-06-05 2021-12-30 Мерк Шарп И Доум Корп. Антитела против lag3 и антигенсвязывающие фрагменты
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN116196426A (zh) 2015-07-16 2023-06-02 百欧肯治疗有限公司 治疗癌症的组合物及方法
WO2017015560A2 (en) * 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
WO2017019757A1 (en) 2015-07-28 2017-02-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
IL287916B2 (en) 2015-07-30 2023-09-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
JP2018525415A (ja) 2015-08-25 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｇｆベータ受容体アンタゴニスト
DK3344654T3 (da) 2015-09-02 2021-01-18 Immutep Sas Anti-lag-3-antistoffer
PH12018500554B1 (en) 2015-09-14 2024-01-24 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
JP6952028B2 (ja) * 2015-09-29 2021-10-20 シャンハイ チャンジアン バイオテクノロジー カンパニー リミテッド Ｐｄ−１抗体およびその使用
CR20180161A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Anticuerpos biespecíficos para pd1 y tim3
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
CN108289951A (zh) * 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
JP2018536404A (ja) 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
JP6945456B2 (ja) * 2015-11-13 2021-10-06 マクロジェニクス，インコーポレーテッド Ｌａｇ‐３結合分子及びその使用方法
US10323090B2 (en) 2015-11-18 2019-06-18 Merck Sharp & Dohme Corp. PD1 and/or LAG3 binders
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
CA3003786C (en) 2015-11-20 2023-09-12 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
JP7349787B2 (ja) 2015-11-23 2023-09-25 ファイヴ プライム セラピューティクス インク 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
US10450318B2 (en) 2015-12-15 2019-10-22 Bristol-Myers Squibb Company CXCR4 receptor antagonists
BR112018012352A2 (pt) * 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
CA3007671A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
AU2016370813A1 (en) 2015-12-18 2018-06-28 Novartis Ag Antibodies targeting CD32b and methods of use thereof
MA43859A (fr) 2016-01-11 2018-11-21 Novartis Ag Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
EP3416946B1 (en) 2016-02-19 2021-09-15 Novartis AG Tetracyclic pyridone compounds as antivirals
US10894835B2 (en) * 2016-03-04 2021-01-19 The Rockefeller University Antibodies to CD40 with enhanced agonist activity
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
US9988416B2 (en) 2016-03-24 2018-06-05 Novartis Ag Alkynyl nucleoside analogs as inhibitors of human rhinovirus
SG11201808909WA (en) 2016-04-13 2018-11-29 Vivia Biotech Sl Ex vivo bite-activated t cells
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
CN109348714A (zh) 2016-05-04 2019-02-15 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
KR20190003686A (ko) 2016-05-04 2019-01-09 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
KR20190004743A (ko) 2016-05-04 2019-01-14 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
KR20190003687A (ko) 2016-05-04 2019-01-09 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
WO2017192813A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
HUE053452T2 (hu) 2016-05-18 2021-07-28 Boehringer Ingelheim Int Anti-PD-1 és anti-LAG3 antitestek rák kezelésére
JP7169195B2 (ja) 2016-05-20 2022-11-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
AU2017283768B2 (en) 2016-06-14 2019-05-23 Novartis Ag Crystalline form of (R)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
LT3472207T (lt) 2016-06-20 2021-05-10 F-Star Delta Limited Surišančios molekulės, kurios suriša pd-l1 ir lag-3
NZ789594A (en) 2016-06-20 2025-07-25 Kymab Ltd Anti-PD-L1 antibodies
BR112018074155A2 (pt) 2016-06-23 2019-03-06 Jiangsu Hengrui Medicine Co., Ltd. anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018014001A1 (en) 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
AU2017297506A1 (en) 2016-07-14 2019-02-21 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
US11198730B2 (en) * 2016-08-15 2021-12-14 Fuso Pharmaceutical Industries, Ltd. Anti-LAG-3 antibody
US11351164B2 (en) 2016-08-26 2022-06-07 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR20230130174A (ko) * 2016-08-30 2023-09-11 젠코어 인코포레이티드 공자극 및 체크포인트 수용체에 결합하는 이중특이적 면역조절 항체
WO2018047109A1 (en) 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals
JP7274413B2 (ja) 2016-09-23 2023-05-16 マレンゴ・セラピューティクス，インコーポレーテッド ラムダ及びカッパ軽鎖を含む多重特異性抗体分子
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
TWI784976B (zh) * 2016-10-13 2022-12-01 大陸商正大天晴藥業集團股份有限公司 抗ｌａｇ-３抗體及組成物
TW201819380A (zh) 2016-10-18 2018-06-01 瑞士商諾華公司 作為抗病毒劑之稠合四環吡啶酮化合物
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
IL307242A (en) 2016-12-07 2023-11-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
TWI812494B (zh) 2017-01-20 2023-08-11 美商阿克思生物科學有限公司 用於治療癌症相關病症之唑嘧啶
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018153340A1 (en) 2017-02-22 2018-08-30 I-Mab Anti-lag-3 antibodies and uses thereof
CA3057687A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
AU2018243754B2 (en) 2017-03-31 2025-04-10 Bristol-Myers Squibb Company Methods of treating tumor
LT3606946T (lt) 2017-04-03 2022-10-25 F. Hoffmann-La Roche Ag Anti-pd-1 antikūno imunokonjugatai su mutantiniu il-2 arba su il-15
IL268620B2 (en) * 2017-04-05 2024-04-01 Hoffmann La Roche Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment
KR102346336B1 (ko) 2017-04-05 2022-01-04 에프. 호프만-라 로슈 아게 Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
CN114984209B (zh) 2017-04-05 2025-08-29 正大天晴药业集团股份有限公司 靶向pd-1、tim-3及lag-3的组合疗法
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
CA3058944A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
SG11201909710XA (en) 2017-04-21 2019-11-28 Kyn Therapeutics Indole ahr inhibitors and uses thereof
EP3615070A1 (en) 2017-04-26 2020-03-04 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
EP3615572A1 (en) * 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
AR111419A1 (es) 2017-04-27 2019-07-10 Novartis Ag Compuestos fusionados de indazol piridona como antivirales
EP4328241A3 (en) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
ES2899616T3 (es) 2017-04-28 2022-03-14 Five Prime Therapeutics Inc Polipéptidos del dominio extracelular del CD80 para su uso en aumentar los linfocitos T de memoria central
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
UY37718A (es) 2017-05-05 2018-11-30 Novartis Ag 2-quinolinonas triciclicas como agentes antibacteriales
CN110621337B (zh) * 2017-05-10 2021-11-09 浙江时迈药业有限公司 抗lag3人单克隆抗体及其用途
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3634417B1 (en) 2017-05-17 2023-07-12 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
CA3060989A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
RS64787B1 (sr) 2017-05-30 2023-11-30 Bristol Myers Squibb Co Lečenje lag-3-pozitivnih tumora
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
AU2018275109A1 (en) 2017-06-01 2020-01-02 Xencor, Inc. Bispecific antibodies that bind CD 123 CD3
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3641812A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
CA3061874A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
AU2018292618A1 (en) 2017-06-27 2019-12-19 Novartis Ag Dosage regimens for anti-TIM-3 antibodies and uses thereof
US11236049B2 (en) 2017-06-30 2022-02-01 Bristol-Myers Squibb Company Amorphous and crystalline forms of IDO inhibitors
EP3652212A4 (en) * 2017-07-13 2021-04-14 Nanjing Leads Biolabs Co., Ltd. LAG-3 BINDING ANTIBODIES AND THEIR USES
IL319798A (en) 2017-07-20 2025-05-01 Novartis Ag ANTI-LAG-3 Antibody Dosage Regimens and Their Uses
KR102709265B1 (ko) 2017-07-28 2024-09-23 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
US11261214B2 (en) 2017-08-04 2022-03-01 Bicycletx Limited Bicyclic peptide ligand specific for CD137
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CA3073051A1 (en) 2017-08-17 2019-02-21 Ikena Oncology, Inc. Ahr inhibitors and uses thereof
CN111372934B (zh) 2017-08-18 2024-04-26 科瑞华生物技术有限公司 Tg02的多晶型形式
AU2018323955A1 (en) * 2017-08-30 2020-03-19 Phanes Therapeutics, Inc. Anti-LAG-3 antibodies and uses thereof
JP7209697B2 (ja) 2017-08-31 2023-01-20 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
EP3676277A1 (en) 2017-08-31 2020-07-08 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3676279B1 (en) 2017-08-31 2021-12-01 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
EP3684365A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND USES OF SUCH
KR102818021B1 (ko) * 2017-10-05 2025-06-10 다이이찌 산쿄 가부시키가이샤 세포 상해성 t 세포 고갈용 조성물
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
EP3694867A1 (en) 2017-10-10 2020-08-19 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019075359A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS AND METHODS OF USE
KR20200064132A (ko) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
KR102747388B1 (ko) 2017-10-16 2024-12-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
CA3079310A1 (en) 2017-10-18 2019-04-25 Vivia Biotech, S.L. Bite-activated car-t cells
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
KR20200074214A (ko) 2017-11-01 2020-06-24 브리스톨-마이어스 스큅 컴퍼니 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체
US11166959B2 (en) 2017-11-06 2021-11-09 Bristol-Myers Squibb Company Isofuranone compounds useful as HPK1 inhibitors
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
JP2021503458A (ja) 2017-11-17 2021-02-12 ノバルティス アーゲー 新規のジヒドロイソキサゾール化合物及びｂ型肝炎治療のためのそれらの使用
KR20200096253A (ko) 2017-11-30 2020-08-11 노파르티스 아게 Bcma-표적화 키메라 항원 수용체, 및 이의 용도
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US11548948B2 (en) 2017-12-19 2023-01-10 F-Star Therapeutics Limited FC binding fragments comprising a PD-L1 antigen-binding site
WO2019123285A1 (en) 2017-12-20 2019-06-27 Novartis Ag Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
WO2019120269A1 (zh) 2017-12-22 2019-06-27 江苏恒瑞医药股份有限公司 Lag-3抗体药物组合物及其用途
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN115925943A (zh) 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
US11306149B2 (en) 2017-12-27 2022-04-19 Bristol-Myers Squibb Company Anti-CD40 antibodies and uses thereof
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
CN111886255B (zh) 2018-01-12 2025-04-04 百时美施贵宝公司 抗tim3抗体及其用途
WO2019141092A1 (zh) * 2018-01-18 2019-07-25 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
KR20200116481A (ko) 2018-01-29 2020-10-12 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
US10793563B2 (en) 2018-01-29 2020-10-06 Merck Patent Gmbh GCN2 inhibitors and uses thereof
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
JP2021511782A (ja) 2018-01-31 2021-05-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 安定化された免疫グロブリンドメイン
JP2021511793A (ja) 2018-01-31 2021-05-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
AU2019222747B2 (en) 2018-02-16 2024-09-05 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
MX2020008791A (es) 2018-02-23 2021-01-08 Bicycletx Ltd Ligandos de peptidos biciclicos multimericos.
WO2019165982A1 (en) 2018-02-28 2019-09-06 WuXi Biologics Ireland Limited Monoclonal antibody against human lag-3, method for preparing same, and use thereof
CN110204614B (zh) * 2018-02-28 2022-07-12 广州誉衡生物科技有限公司 抗人lag-3单克隆抗体及其制备方法和用途
CN111801331A (zh) 2018-02-28 2020-10-20 诺华股份有限公司 吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
UA127897C2 (uk) 2018-03-05 2024-02-07 Аркус Байосайєнсіз, Інк. Інгібітори аргінази
KR20200130362A (ko) 2018-03-08 2020-11-18 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
JP7438180B2 (ja) 2018-03-20 2024-02-26 ウーシー バイオロジクス アイルランド リミテッド 新規抗ｌａｇ－３抗体ポリペプチド
AU2019239747A1 (en) 2018-03-21 2020-10-08 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
WO2019192432A1 (zh) 2018-04-02 2019-10-10 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
CN110343178B (zh) * 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 抗人lag-3单克隆抗体及其应用
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
JP2021522211A (ja) 2018-04-16 2021-08-30 アリーズ セラピューティクス， インコーポレイテッド Ｅｐ４阻害剤およびその使用
EP3781596A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
WO2019213340A1 (en) 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
KR20210016426A (ko) 2018-06-01 2021-02-15 노파르티스 아게 Cd123 및 cd3에 결합하는 이중특이적 항체의 투약
CN119185533A (zh) 2018-06-11 2024-12-27 耶鲁大学 新型免疫检查点抑制剂
CN110606892B (zh) * 2018-06-14 2023-09-26 华博生物医药技术（上海）有限公司 一种高亲和力高生物活性的lag-3抗体及其应用
CN110615840A (zh) * 2018-06-19 2019-12-27 信达生物制药(苏州)有限公司 全人源的抗lag-3抗体及其应用
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
ES2950007T3 (es) 2018-06-27 2023-10-04 Bristol Myers Squibb Co Compuestos de naftiridinona útiles como activadores de células T
BR112020026681A2 (pt) 2018-06-27 2021-04-06 Bristol-Myers Squibb Company Compostos naftiridinona substituídos úteis como ativadores de célula t
US11945864B2 (en) 2018-06-29 2024-04-02 Y-Biologics Inc. Monoclonal antibody specifically binding to LAG-3 and use thereof
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
EP3820904A2 (en) 2018-07-09 2021-05-19 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
RS64759B1 (sr) 2018-07-10 2023-11-30 Novartis Ag 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-dion derivati i njihova primena u lečenju bolesti zavisnih od cink prsta 2 (ikzf2) iz porodice ikaros
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
EP3820898B1 (en) 2018-07-12 2025-09-03 invoX Pharma Limited Antibody molecules that bind cd137 and ox40
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
SG11202100170RA (en) 2018-07-12 2021-02-25 F Star Beta Ltd Antibody molecules that bind pd-l1 and cd137
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
SG11202100267TA (en) 2018-07-18 2021-02-25 Arcus Biosciences Inc Solid forms of an azolopyrimidine compound
BR112021000727A2 (pt) 2018-07-20 2021-04-13 Surface Oncology, Inc. Composições anti-cd112r e métodos
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12145927B2 (en) 2018-07-23 2024-11-19 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
AU2019309849A1 (en) * 2018-07-26 2021-03-18 Bristol-Myers Squibb Company LAG-3 combination therapy for the treatment of cancer
CN110172099B (zh) * 2018-08-16 2020-03-03 上海健信生物医药科技有限公司 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
EP3854805A4 (en) 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
TWI791894B (zh) 2018-09-21 2023-02-11 大陸商信達生物製藥（蘇州）有限公司 新型白介素２及其用途
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
BR112021005769A2 (pt) 2018-09-25 2021-07-06 Harpoon Therapeutics Inc proteínas de ligação a dll3 e métodos de uso
US20220242957A1 (en) 2018-09-27 2022-08-04 Marengo Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
MX2021003459A (es) 2018-09-29 2021-06-18 Novartis Ag Proceso de fabricacion de un compuesto para la inhibicion de la actividad de shp2.
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
CN113423734A (zh) 2018-10-12 2021-09-21 Xencor股份有限公司 靶向PD-1的IL-15/IL-15RαFC融合蛋白及其在联合疗法中的应用
SG11202102864XA (en) * 2018-10-19 2021-05-28 Bristol Myers Squibb Co Combination therapy for melanoma
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
KR20210092769A (ko) 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 항-nkg2a 항체 및 그의 용도
CA3120196A1 (en) 2018-11-16 2020-05-22 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
SG11202105424PA (en) 2018-11-30 2021-06-29 Kymera Therapeutics Inc Irak degraders and uses thereof
JP2022511029A (ja) 2018-12-04 2022-01-28 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3897853A1 (en) 2018-12-20 2021-10-27 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
AU2019408408A1 (en) 2018-12-21 2021-06-03 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
CN113227137A (zh) 2018-12-21 2021-08-06 诺华股份有限公司 IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途
US20220056123A1 (en) 2018-12-21 2022-02-24 Novartis Ag Use of il-1beta binding antibodies
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
HUE072069T2 (hu) 2019-02-12 2025-10-28 Sumitomo Pharma America Inc 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
CN113329792B (zh) 2019-02-15 2024-06-28 诺华股份有限公司 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
CN111620949A (zh) 2019-02-28 2020-09-04 三生国健药业（上海）股份有限公司 结合人lag-3的抗体、其制备方法和用途
JP2022524559A (ja) 2019-03-12 2022-05-06 アーカス バイオサイエンシーズ，インコーポレーテッド がん遺伝子によって促進されるがんの処置
JP7684947B2 (ja) 2019-03-19 2025-05-28 フンダシオ プリバダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル エブロン 癌の治療のための併用療法
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
EP3941463A1 (en) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
MX2021011753A (es) 2019-03-26 2022-01-31 Univ Michigan Regents Degradadores de moleculas peque?as de stat3.
EP3947403A1 (en) 2019-03-29 2022-02-09 The Regents Of The University Of Michigan Stat3 protein degraders
CN113874397A (zh) 2019-03-29 2021-12-31 艾库斯生物科学有限公司 利用鉴定的腺苷指纹治疗癌症
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
SG11202110829YA (en) 2019-04-05 2021-10-28 Kymera Therapeutics Inc Stat degraders and uses thereof
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
CN120939219A (zh) 2019-05-13 2025-11-14 瑞泽恩制药公司 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合
US20230295087A1 (en) 2019-05-13 2023-09-21 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
KR20220016156A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
TW202108559A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
AU2020291936A1 (en) 2019-06-12 2022-02-03 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
AU2020291464A1 (en) 2019-06-12 2022-02-03 Vanderbilt University Amino acid transport inhibitors and the uses thereof
WO2020259593A1 (zh) * 2019-06-24 2020-12-30 信达生物制药(苏州)有限公司 包含抗lag-3抗体的制剂、其制备方法及其用途
CN115443329A (zh) 2019-06-27 2022-12-06 乔治华盛顿大学国会特许非营利公司 Hdac6激活的巨噬细胞、其组合物及用途
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
IT201900011676A1 (it) 2019-07-12 2021-01-12 St Superiore Di Sanita Anticorpo ricombinante umano contro il recettore di membrana LAG3, suoi usi medici e diagnostici.
PH12021553233A1 (en) 2019-07-16 2022-09-19 Univ Michigan Regents Imidazopyrimidines as eed inhibitors and the use thereof
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN114641337A (zh) 2019-08-27 2022-06-17 密歇根大学董事会 Cereblon e3连接酶抑制剂
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
EP4027995A4 (en) 2019-09-13 2023-08-23 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND THEIR APPLICATIONS
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4031241A1 (en) 2019-09-19 2022-07-27 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
EP4031575A1 (en) 2019-09-19 2022-07-27 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
US20220348653A1 (en) 2019-09-22 2022-11-03 Bristol-Myers Squibb Company Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
TW202535873A (zh) 2019-09-26 2025-09-16 瑞士商諾華公司 抗病毒吡唑并吡啶酮化合物
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
KR20220088438A (ko) * 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CA3157665A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
TW202128166A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 組合療法
CN114599372A (zh) 2019-11-04 2022-06-07 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
BR112022008191A2 (pt) 2019-11-08 2022-07-12 Bristol Myers Squibb Co Terapia com antagonista de lag-3 para melanoma
KR20220103753A (ko) 2019-11-19 2022-07-22 브리스톨-마이어스 스큅 컴퍼니 헬리오스 단백질의 억제제로서 유용한 화합물
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
CA3159071A1 (en) 2019-11-26 2021-06-03 Tamar I. ROSENBAUM Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
MX2022007576A (es) 2019-12-17 2022-09-23 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
AU2020406350A1 (en) 2019-12-20 2022-08-11 Novartis Ag Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
BR112022012222A2 (pt) 2019-12-23 2022-09-13 Bristol Myers Squibb Co Derivados de piperazina substituídos úteis como ativadores de células t
IL294269A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinolinonyl piperazine compounds useful as t cell activators
ES3038401T3 (en) 2019-12-23 2025-10-13 Bristol Myers Squibb Co Substituted quinazolinyl compounds useful as t cell activators
IL294150A (en) 2019-12-23 2022-08-01 Kymera Therapeutics Inc Smarca joints and their uses
IL294273A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted heteroaryl compounds are useful as t-cell activators
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CA3166898A1 (en) 2020-01-06 2021-07-15 Hifibio (Hk) Limited Anti-tnfr2 antibody and uses thereof
BR112022013494A2 (pt) 2020-01-07 2022-09-13 Hifibio Hk Ltd Anticorpo anti-galectina-9 e usos do mesmo
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
KR20220128389A (ko) 2020-01-17 2022-09-20 노파르티스 아게 골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
CN111205371B (zh) * 2020-01-22 2022-03-29 北京吉尔麦迪生物医药科技有限公司 一种抗淋巴细胞激活基因3的抗体及应用
TW202146452A (zh) 2020-02-28 2021-12-16 瑞士商諾華公司 結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
US20230140384A1 (en) 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
KR20220155593A (ko) 2020-03-19 2022-11-23 아르커스 바이오사이언시즈 인코포레이티드 Hif-2알파의 억제제로서의 테트랄린 및 테트라히드로퀴놀린 화합물
MX2022011602A (es) 2020-03-19 2023-01-04 Kymera Therapeutics Inc Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos.
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
US20230159573A1 (en) 2020-03-26 2023-05-25 The Regents Of The University Of Michigan Small molecule stat protein degraders
CN115666648A (zh) * 2020-04-03 2023-01-31 索伦托药业有限公司 结合lag3的工程化抗体
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. DEUTERED IRAQ DEGRADERS AND USES THEREOF
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN115867355A (zh) * 2020-06-30 2023-03-28 艾瑞克斯疗法有限公司 用于治疗系统性硬化病的抗s100a4抗体
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
US20230233690A1 (en) 2020-07-10 2023-07-27 The Regents Of The University Of Michigan Androgen receptor protein degraders
WO2022011204A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
KR20230044480A (ko) 2020-07-30 2023-04-04 카이메라 쎄라퓨틱스 인코포레이티드 돌연변이 림프종의 치료 방법
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
IL300537A (en) 2020-08-10 2023-04-01 Gv20 Therapeutics Llc Compositions and methods for treating autoimmune diseases and cancer by targeting IGSF8
CN116194480A (zh) 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
EP4196792A1 (en) 2020-08-17 2023-06-21 BicycleTX Limited Bicycle conjugates specific for nectin-4 and uses thereof
JP2023540248A (ja) 2020-08-26 2023-09-22 マレンゴ・セラピューティクス，インコーポレーテッド Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法
AU2021331476A1 (en) 2020-08-28 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
KR20230061430A (ko) 2020-08-31 2023-05-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 면역요법
WO2022072820A1 (en) 2020-10-02 2022-04-07 Dracen Pharmaceuticals, Inc. Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof
US20230416382A1 (en) 2020-10-14 2023-12-28 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
IL301907A (en) 2020-10-23 2023-06-01 Bristol Myers Squibb Co Lag-3 antagonist therapy for lung cancer
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
CA3200814A1 (en) 2020-12-02 2022-06-09 Alfredo C. Castro Tead inhibitors and uses thereof
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
EP4259149A1 (en) 2020-12-08 2023-10-18 Infinity Pharmaceuticals, Inc. Eganelisib for use in the treatment of pd-l1 negative cancer
CN114621344B (zh) * 2020-12-10 2022-08-30 北京东方百泰生物科技股份有限公司 一种抗lag-3单克隆抗体的纯化方法
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
CN116964050A (zh) 2020-12-16 2023-10-27 戈萨默生物服务公司 可用作t细胞激活剂的化合物
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
SI4267105T1 (sl) 2020-12-28 2025-07-31 Bristol-Myers Squibb Company Sestave protiteles in načini njihove uporabe
AU2021413371A1 (en) 2020-12-30 2023-07-13 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
JP2024506839A (ja) 2021-01-29 2024-02-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム キナーゼ阻害剤を用いてがんを処置する方法
AU2022215844A1 (en) 2021-02-02 2023-09-14 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CN117098757A (zh) 2021-02-02 2023-11-21 里米诺生物科学有限公司 Gpr84拮抗剂和其用途
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
CN117120090A (zh) 2021-02-12 2023-11-24 林伯士萨顿公司 Hpk1拮抗剂和其用途
AU2022221124A1 (en) 2021-02-12 2023-08-03 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
AU2022220869A1 (en) 2021-02-15 2023-08-24 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
AU2022220043A1 (en) 2021-02-15 2023-08-31 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
WO2022187419A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
JP2024510176A (ja) 2021-03-08 2024-03-06 ブループリント メディシンズ コーポレイション Ｍａｐ４ｋ１阻害剤
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
EP4313127A1 (en) 2021-03-29 2024-02-07 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
MX2023011408A (es) 2021-04-05 2024-01-18 Bristol Myers Squibb Co Compuestos de oxoisoindolina sustituidos con piridinilo para el tratamiento de cancer.
AR125298A1 (es) 2021-04-06 2023-07-05 Bristol Myers Squibb Co Compuestos de oxoisoindolina sustituidos con piridinilo
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
US20240279225A1 (en) 2021-04-08 2024-08-22 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
EP4319756A4 (en) 2021-04-09 2025-02-26 Nimbus Clio, Inc. CBL-B MODULATORS AND USES THEREOF
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
JP2024514879A (ja) 2021-04-16 2024-04-03 イケナ オンコロジー， インコーポレイテッド Ｍｅｋ阻害剤及びその使用
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
JP2024521712A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ阻害化合物
TW202313602A (zh) 2021-05-21 2023-04-01 美商阿克思生物科學有限公司 Axl化合物
MX2024000674A (es) 2021-07-13 2024-02-07 BioNTech SE Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
AU2022312496A1 (en) 2021-07-14 2024-02-22 Blueprint Medicines Corporation Heterocyclic compounds as map4k1 inhibitors
TW202321238A (zh) 2021-07-15 2023-06-01 美商纜圖藥品公司 Ｍａｐ４ｋ１抑制劑
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
EP4399206A1 (en) 2021-09-08 2024-07-17 Redona Therapeutics, Inc. Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
EP4410835A4 (en) * 2021-09-29 2025-09-24 Akeso Biopharma Inc ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
JP2024541969A (ja) 2021-10-29 2024-11-13 アーカス バイオサイエンシズ インコーポレイティド Ｈｉｆ－２アルファの阻害剤及びその使用方法
CN118302168A (zh) 2021-10-29 2024-07-05 凯麦拉医疗公司 Irak4降解剂和其制备
CN118176214A (zh) 2021-10-29 2024-06-11 百时美施贵宝公司 血液癌症的lag-3拮抗剂疗法
EP4448761A1 (en) 2021-12-16 2024-10-23 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
KR20240135661A (ko) 2022-01-26 2024-09-11 브리스톨-마이어스 스큅 컴퍼니 간세포성 암종에 대한 조합 요법
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
EP4472967A2 (en) 2022-01-31 2024-12-11 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2025503312A (ja) 2022-02-01 2025-01-30 アルビナス・オペレーションズ・インコーポレイテッド Ｄｇｋ標的化化合物およびその使用
TWI864587B (zh) 2022-02-14 2024-12-01 美商基利科學股份有限公司 抗病毒吡唑并吡啶酮化合物
CA3251366A1 (en) 2022-02-25 2023-08-31 Bristol Myers Squibb Co POLYTHERAPY AGAINST COLORECTAL CARCINOMA
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
EP4493195A1 (en) 2022-03-15 2025-01-22 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN114874324B (zh) * 2022-05-13 2023-02-03 苏州旭光科星抗体生物科技有限公司 一种检测可溶性lag-3蛋白含量的酶联免疫检测试剂盒及应用
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
CA3258064A1 (en) 2022-06-02 2023-12-07 Bristol Myers Squibb Co ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE
CN119562973A (zh) 2022-07-11 2025-03-04 基诺富公司 细胞激素融合蛋白质
US20240124490A1 (en) 2022-07-15 2024-04-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
EP4558501A1 (en) 2022-07-20 2025-05-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
KR20250057800A (ko) 2022-08-02 2025-04-29 리미널 바이오사이언시스 리미티드 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
IL318576A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd Pyridoxine-substituted GPR84 antagonists and their uses
WO2024036100A1 (en) 2022-08-08 2024-02-15 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
JP2025526727A (ja) 2022-08-11 2025-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式テトラヒドロチアゼピン誘導体
TW202417439A (zh) 2022-08-11 2024-05-01 瑞士商赫孚孟拉羅股份公司 雙環四氫噻吖呯衍生物
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
MA71728A (fr) 2022-08-11 2025-05-30 F. Hoffmann-La Roche Ag Dérivés bicycliques de tétrahydrothiazépine
TW202421150A (zh) 2022-09-14 2024-06-01 美商阿克思生物科學有限公司 艾魯美冷之分散體
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
AU2023364215A1 (en) 2022-10-20 2025-04-24 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds
WO2024089417A1 (en) 2022-10-24 2024-05-02 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor
CN120187419A (zh) 2022-10-24 2025-06-20 癌症研究技术有限公司 通过氧化还原状态调节剂使肿瘤对检查点抑制剂敏感
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
CN120731228A (zh) 2022-12-21 2025-09-30 百时美施贵宝公司 肺癌的组合疗法
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN115819595B (zh) * 2023-01-03 2023-05-16 上海百英生物科技股份有限公司 一种抗lag3纳米抗体及其制备方法与应用
EP4649173A1 (en) 2023-01-13 2025-11-19 Akrivia Biomedics Limited Method of profiling diseases
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
IL323023A (en) 2023-03-13 2025-10-01 Regeneron Pharma Combination of PD-1 and LAG-3 inhibitors for improved efficacy in melanoma treatment
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
AU2024252845A1 (en) 2023-04-06 2025-10-16 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
US20240425497A1 (en) 2023-05-05 2024-12-26 Arcus Biosciences, Inc. Cbl-b Inhibitors and Methods of Use Thereof
CN121057732A (zh) 2023-05-08 2025-12-02 百时美施贵宝公司 经取代的苯基噁唑酮化合物
AU2024269298A1 (en) 2023-05-10 2025-11-27 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
WO2024233853A2 (en) * 2023-05-11 2024-11-14 Elixiron Immunotherapeutics (hong Kong) Limited A combination comprising lag-3 targeting moiety and interleukin-10
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024249540A1 (en) 2023-05-31 2024-12-05 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024249894A2 (en) 2023-06-02 2024-12-05 Arcus Biosciences, Inc. Biomarkers for predicting cancer treatment efficacy
WO2024254227A1 (en) 2023-06-07 2024-12-12 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024264017A2 (en) 2023-06-23 2024-12-26 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025038857A1 (en) 2023-08-16 2025-02-20 Arcus Biosciences, Inc. TETRALINS TARGETING MUTANT HIF-2α
AR133696A1 (es) 2023-09-02 2025-10-22 Bristol Myers Squibb Co Compuestos de fenil oxooxazolil piperidinadiona sustituida
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
TW202525792A (zh) 2023-09-13 2025-07-01 美商必治妥美雅史谷比公司 經取代之側氧異吲哚啉基哌啶－２，６－二酮化合物
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
WO2025068452A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025068461A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025076299A1 (en) 2023-10-06 2025-04-10 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US20250145590A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096979A1 (en) 2023-11-02 2025-05-08 Arcus Biosciences, Inc. Thiazole compounds as kit inhibitors and methods of use thereof
WO2025106736A2 (en) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025132831A1 (en) 2023-12-19 2025-06-26 Universite D'aix-Marseille N-heteroaryl derivatives and uses thereof for treating cancer
US20250230173A1 (en) 2023-12-20 2025-07-17 Arcus Biosciences, Inc. Salt forms of an axl inhibitor
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1
WO2025184211A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025193571A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193573A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193574A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193569A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193583A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193572A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound
WO2025193770A1 (en) 2024-03-13 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1081681A (en) 1910-08-31 1913-12-16 Otis Elevator Co Alternating-current-motor control.
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
GB9108652D0 (en) 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2144043C (en) 1992-09-16 2005-01-18 Dennis R. Burton Human neutralizing monoclonal antibodies to respiratory syncytial virus
JP3919830B2 (ja) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
AU1866895A (en) 1994-01-04 1995-08-01 Scripps Research Institute, The Human monoclonal antibodies to herpes simplex virus and methods therefor
EP0758383B1 (fr) 1994-05-06 2007-01-24 Institut Gustave Roussy Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
JP2000508226A (ja) 1995-07-21 2000-07-04 アプライド リサーチ システムズ アース ホールディング エヌ．ヴィ． Ｌａｇ−３タンパク質によるｔｈ１リンパ球を検出、同定、単離並びに選択的に標識およびターゲッティングする方法
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
JP2002502324A (ja) 1996-03-07 2002-01-22 イーストマン ケミカル カンパニー 近赤外蛍光安全保障熱転写印刷及びマーキングリボン
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
AU728911B2 (en) 1996-11-28 2001-01-18 Institut Gustave Roussy Mutants of the LAG-3 proteins, products for the expression of these mutants and use
EP0941329B1 (en) 1996-11-29 2004-07-21 Applied Research Systems ARS Holding N.V. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2001523958A (ja) * 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
WO2000005266A1 (en) 1998-07-21 2000-02-03 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
AU772676B2 (en) 1998-12-23 2004-05-06 Amgen Fremont Inc. Human monoclonal antibodies to CTLA-4
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
MXPA02001877A (es) 1999-08-23 2002-08-20 Dana Farber Cancer Inst Inc Pd-1, un receptor para b7-4, y usos del mismo.
AU784012B2 (en) 1999-08-24 2006-01-12 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
CN101940189A (zh) 2000-11-30 2011-01-12 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US20040121322A9 (en) 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
KR100770065B1 (ko) 2001-05-11 2007-10-24 기린 파마 가부시끼가이샤 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는비인간 동물
WO2002096910A1 (en) 2001-05-31 2002-12-05 Medarex, Inc. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
ATE448320T1 (de) 2001-09-19 2009-11-15 Alexion Pharma Inc Manipulierte matrizen und ihre verwendung bei der single-primer-amplifikation
EP1295895B1 (en) 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
US20030228319A1 (en) 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
WO2004004771A1 (ja) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
WO2004039956A2 (en) 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050009136A1 (en) 2003-02-19 2005-01-13 Dyax Corporation PAPP-A ligands
SI1897548T2 (sl) 2003-02-28 2024-09-30 The Johns Hopkins University Regulacija celic T
AU2004279441B2 (en) 2003-10-08 2010-07-01 The Feinstein Institute For Medical Research Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia
PT1711207E (pt) * 2003-12-10 2013-02-13 Medarex Inc Anticorpos alfa interferão e seus usos
ES2403055T3 (es) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anticuerpos anti-P-selectina
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
EP1747021B1 (en) 2004-05-19 2015-09-09 E. R. Squibb & Sons, L.L.C. Self-immolative linkers and drug conjugates
US8198415B2 (en) 2004-07-20 2012-06-12 Symphogen A/S Anti-rhesus D recombinant polyclonal antibody
US7329737B2 (en) 2004-08-03 2008-02-12 Dyax Corp. Antibodies that bind hK-1
US20090252741A1 (en) 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
EP1802345A2 (en) 2004-10-01 2007-07-04 Medarex, Inc. Methods of treating cd30 positive lymphomas
PL1810026T3 (pl) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
RU2421466C2 (ru) 2005-02-18 2011-06-20 Медарекс, Инк. Выделенное антитело против специфического мембранного антигена простаты (psma) и способ ингибирования роста клеток, экспрессирующих psma
MX2007010603A (es) 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal.
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
JP4361545B2 (ja) 2005-05-09 2009-11-11 小野薬品工業株式会社 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
EP2354163A3 (en) 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
US7847105B2 (en) 2005-10-26 2010-12-07 Medarex, Inc. Methods and compounds for preparing CC-1065 analogs
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
AU2006322445B2 (en) 2005-12-05 2011-05-12 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
EP2078732B1 (en) 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
NZ596834A (en) * 2006-08-18 2013-06-28 Novartis Ag Prlr-specific antibody and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
JP2010519310A (ja) 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
HUE029164T2 (hu) 2007-09-14 2017-02-28 Univ Brussel Vrije Humán antigén-prezentáló sejtek T-sejteket stimuláló képességének fokozása és azok alkalmazása vakcinázásra
WO2009045957A1 (en) 2007-10-01 2009-04-09 Medarex, Inc. Human antibodies that bind mesothelin, and uses thereof
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
TW200938223A (en) 2007-11-30 2009-09-16 Medarex Inc Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7)
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
JP2012510429A (ja) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよびその使用方法
KR20250091300A (ko) 2008-12-09 2025-06-20 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
CN105440133A (zh) * 2009-07-15 2016-03-30 Aimm医疗股份公司 革兰氏阳性细菌特异性结合化合物
DK2504364T3 (da) 2009-11-24 2017-11-06 Medimmune Ltd Målrettede bindemidler mod b7-h1
RU2567808C2 (ru) * 2010-07-14 2015-11-10 Мерк Шарп Энд Домэ Корп. Моноклональное антитело против addl и его применения
WO2012054438A1 (en) * 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
SG10201700698WA (en) 2012-05-15 2017-02-27 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
HRP20201113T1 (hr) 2013-03-15 2020-10-30 Glaxosmithkline Intellectual Property Development Limited Vežući proteini protiv lag-3
MX2016000750A (es) 2013-08-02 2016-08-05 Aduro Biotech Holdings Europe B V Combinacion de agonistas de cd27 e inhibicion del punto de control inmunologico para estimulacion del sistema inmunologico.
DK3508502T5 (da) 2013-09-20 2024-09-02 Bristol Myers Squibb Co Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
HUE057817T2 (hu) 2014-01-28 2022-06-28 Bristol Myers Squibb Co Anti-LAG-3 antitestek haematológiai malignitások kezelésére
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020103301A (ja) * 2012-07-02 2020-07-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ リンパ球活性化遺伝子−３（ｌａｇ−３）へ結合する抗体の最適化およびその使用
JP7009531B2 (ja) 2012-07-02 2022-02-10 ブリストル－マイヤーズ スクイブ カンパニー リンパ球活性化遺伝子－３（ｌａｇ－３）へ結合する抗体の最適化およびその使用

Also Published As

Publication number Publication date
AU2019204803C1 (en) 2023-06-29
US9505839B2 (en) 2016-11-29
KR102461102B1 (ko) 2022-10-31
JP2015527880A (ja) 2015-09-24
EA201590138A1 (ru) 2015-07-30
US20180371087A1 (en) 2018-12-27
TWI771721B (zh) 2022-07-21
AR091649A1 (es) 2015-02-18
PL3795592T3 (pl) 2024-10-07
DK2867258T3 (en) 2017-10-02
DK3795592T3 (da) 2024-10-14
TW201938198A (zh) 2019-10-01
CA2877746A1 (en) 2014-01-09
PE20241623A1 (es) 2024-08-07
PH12014502854A1 (en) 2015-02-23
PT3275899T (pt) 2020-11-17
MX365417B (es) 2019-06-03
CY1119563T1 (el) 2018-03-07
AU2013286914B2 (en) 2017-06-29
SI3795592T1 (sl) 2024-10-30
TW202313688A (zh) 2023-04-01
CY1123609T1 (el) 2022-03-24
KR20240168469A (ko) 2024-11-29
MY197544A (en) 2023-06-22
AU2013286914A1 (en) 2015-01-29
AU2019204803A1 (en) 2019-07-25
DK3275899T3 (da) 2020-11-30
US11345752B2 (en) 2022-05-31
FIC20230009I1 (fi) 2023-02-09
CL2014003637A1 (es) 2015-03-27
LTC2867258I2 (enExample) 2025-06-10
HUE069061T2 (hu) 2025-02-28
TW202432599A (zh) 2024-08-16
PH12021552200A1 (en) 2022-05-02
EP2867258A1 (en) 2015-05-06
EP3275899A1 (en) 2018-01-31
AR125268A2 (es) 2023-06-28
NO2023008I1 (no) 2023-02-07
JP2022064901A (ja) 2022-04-26
CA3161329A1 (en) 2014-01-09
EP3795592A1 (en) 2021-03-24
WO2014008218A1 (en) 2014-01-09
MY169383A (en) 2019-03-26
RS56398B1 (sr) 2017-12-29
AU2021225177A1 (en) 2021-09-30
LT2867258T (lt) 2017-09-11
SMT201700449T1 (it) 2017-11-15
NL301205I2 (nl) 2023-05-24
PL2867258T3 (pl) 2017-11-30
TWI617581B (zh) 2018-03-11
TWI701045B (zh) 2020-08-11
KR20230159625A (ko) 2023-11-21
SG11201408780XA (en) 2015-01-29
SG10201610960YA (en) 2017-02-27
US10266591B2 (en) 2019-04-23
IL236517A0 (en) 2015-02-26
EP2867258B1 (en) 2017-06-28
RS65997B1 (sr) 2024-10-31
NO2023020I1 (no) 2023-05-03
PT2867258T (pt) 2017-08-31
US20190256594A1 (en) 2019-08-22
AU2019204803B2 (en) 2021-06-10
TW201726743A (zh) 2017-08-01
TW201406784A (zh) 2014-02-16
ES2831406T3 (es) 2021-06-08
CY2022035I1 (el) 2023-01-05
RS61084B1 (sr) 2020-12-31
TWI662046B (zh) 2019-06-11
UY34887A (es) 2013-12-31
PE20150221A1 (es) 2015-02-19
LTPA2022015I1 (enExample) 2022-12-12
ES2987734T3 (es) 2024-11-18
TWI576355B (zh) 2017-04-01
MX2015000116A (es) 2015-04-14
CO7170127A2 (es) 2015-01-28
JP2020103301A (ja) 2020-07-09
HUE034553T2 (en) 2018-02-28
LUC00286I2 (enExample) 2025-05-12
SI2867258T1 (sl) 2017-10-30
LT3795592T (lt) 2024-09-25
US20230077348A1 (en) 2023-03-16
CY2022035I2 (el) 2023-01-27
US20170137514A1 (en) 2017-05-18
PE20191759A1 (es) 2019-12-12
PE20191324A1 (es) 2019-09-24
AR129651A2 (es) 2024-09-18
US20250136684A1 (en) 2025-05-01
EP3795592B1 (en) 2024-07-24
AU2017221874B2 (en) 2019-05-02
LT3275899T (lt) 2020-12-10
TW201831515A (zh) 2018-09-01
AU2025200257A1 (en) 2025-02-20
HRP20201852T8 (hr) 2021-06-25
HRP20201852T1 (hr) 2021-01-08
NZ628528A (en) 2016-07-29
FR22C1057I2 (fr) 2023-12-15
JP6668405B2 (ja) 2020-03-18
AU2017221874A1 (en) 2017-09-21
TW202118789A (zh) 2021-05-16
SMT202400395T1 (it) 2024-11-15
MY197322A (en) 2023-06-13
EA202090227A1 (ru) 2020-05-31
PT3795592T (pt) 2024-09-17
HRP20171315T1 (hr) 2017-10-20
PH12014502854B1 (en) 2015-02-23
BR112014032999A2 (pt) 2017-08-01
CN108101991A (zh) 2018-06-01
KR20150023909A (ko) 2015-03-05
SMT202000628T1 (it) 2021-01-05
IL236517B (en) 2018-06-28
MX2019006411A (es) 2019-08-14
HK1207386A1 (en) 2016-01-29
EP4553086A2 (en) 2025-05-14
EP3275899B1 (en) 2020-08-26
HRP20241357T1 (hr) 2024-12-20
ES2638545T3 (es) 2017-10-23
KR20200075891A (ko) 2020-06-26
US10377824B2 (en) 2019-08-13
SI3275899T1 (sl) 2020-11-30
EA035013B1 (ru) 2020-04-17
CN104411723B (zh) 2018-01-30
KR20220150417A (ko) 2022-11-10
JP2024041966A (ja) 2024-03-27
FI3795592T3 (fi) 2024-10-01
KR102126596B1 (ko) 2020-06-24
JP2018126149A (ja) 2018-08-16
US20150307609A1 (en) 2015-10-29
HK1249535A1 (en) 2018-11-02
FR22C1057I1 (fr) 2023-01-06
NL301205I1 (enExample) 2023-04-19
BR112014032999B1 (pt) 2022-10-18
US20140093511A1 (en) 2014-04-03
KR102290633B1 (ko) 2021-08-19
CN108101991B (zh) 2022-02-11
CA2877746C (en) 2022-07-19
TN2014000536A1 (en) 2016-03-30
HUE052406T2 (hu) 2021-04-28
HUS2300002I1 (hu) 2023-01-28
JP7009531B2 (ja) 2022-02-10
CN104411723A (zh) 2015-03-11
KR20210102485A (ko) 2021-08-19

Similar Documents

Publication Publication Date Title
JP7009531B2 (ja) リンパ球活性化遺伝子－３（ｌａｇ－３）へ結合する抗体の最適化およびその使用
JP2025094193A (ja) リンパ球活性化遺伝子－３（ｌａｇ－３）へ結合するヒト抗体およびその使用
HK40051182A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
HK40051182B (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
HK1249535B (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA044665B1 (ru) Фармацевтическая композиция, содержащая анти-lag-3 антитело и анти-pd-1 антитело
HK1207386B (en) Optimization of human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180403

R150 Certificate of patent or registration of utility model

Ref document number: 6320376

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250